Author Archives: admin


Stem Cell Clinic > Articles by: admin

Adipose Tissue-Derived Stem Cells (ADSCS) Market Expected to Witness High Growth over the Forecast 2027 – BCFocus

By Stell Cell Research

Data Bridge Market Research has recently published the Global research Report TitledAdipose Tissue-Derived Stem Cells (ADSCS) Market.

TheAdipose Tissue-Derived Stem Cells (ADSCS) Marketreport gives acquaintance about all the recent developments, product launches, joint ventures, mergers and acquisitions by several key players and brands while also giving a synopsis of market definition, classifications, and market trends. It lends a hand to companies to take decisive actions to deal with threats in a niche market. This market research report also provides thorough information about target markets or customers. Global Adipose Tissue-Derived Stem Cells (ADSCS) Market report is a sure-fire solution that businesses can adopt to thrive in this swiftly changing marketplace. For outstanding business growth, companies must take upmarket research report service which has become enough vital in todays market place.

Adipose tissue-derived stem cells (ADSCS) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account grow at a CAGR of 6.1% in the above-mentioned forecast period. The accelerating application of adipose tissue-derived stem cells (ADSCS) in the regenerative medicines research, development of cell linage, tissue engendering, bone and cartilage regeneration are driving the exponential growth of adipose tissue-derived stem cells (ADSCS) market during the forecast period of 2020 to 2027.

This report examines all the key factors influencing the growth of Adipose Tissue-Derived Stem Cells (ADSCS) market, including demand-supply scenario, pricing structure, profit margins, production and value chain analysis. Regional assessment of Adipose Tissue-Derived Stem Cells (ADSCS) market unlocks a plethora of untapped opportunities in regional and domestic marketplaces. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, the scope of NPD in new markets, pricing strategies, innovation possibilities and much more.

Get Free Sample Copy of the Report to Understand the Structure of the Complete Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

The Global Adipose Tissue-Derived Stem Cells (ADSCS) Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Adipose Tissue-Derived Stem Cells (ADSCS) market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Adipose Tissue-Derived Stem Cells (ADSCS) Market in each region. Various methodological tools are used to analyze the growth of the worldwide Adipose Tissue-Derived Stem Cells (ADSCS) market.

Prominent Key Players Covered in the report:

Antria Inc., CELGENE CORPORATION, pluristem, Tissue Genesis, Cytori Therapeutics Inc., PRECIGEN, Mesoblast Ltd, CORESTEM, Inc, among other domestic and global players.

Major Regions as Follows:

North America (USA, Canada and Mexico)

Europe (Germany, France, the United Kingdom, Netherlands, Russia , Italy and Rest of Europe)

Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia, rest of countries etc.)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Nigeria and South Africa)

A complete value chain of the global Adipose Tissue-Derived Stem Cells (ADSCS) market is presented in the research report. It is associated with the review of the downstream and upstream components of the Adipose Tissue-Derived Stem Cells (ADSCS) Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global Adipose Tissue-Derived Stem Cells (ADSCS) market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Adipose Tissue-Derived Stem Cells (ADSCS) market.

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

How Does This Market Insights Help?

Key Pointers Covered in the Adipose Tissue-Derived Stem Cells (ADSCS) Market Industry Trends and Forecast

Reasons to Purchase this Report

Request Free Sample PDF (including COVID19 Impact Analysis) of Adipose Tissue-Derived Stem Cells (ADSCS) MarketReport@https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

Market Dynamics:The Adipose Tissue-Derived Stem Cells (ADSCS) report also demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead. It also studies the key markets and mentions the various regions i.e. the geographical spread of the industry.

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Market Drivers

Market Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Adipose Tissue-Derived Stem Cells (ADSCS) Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report givesinformation such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

Get Enquiry About This Comprehensive Report: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:Corporatesales@databridgemarketresearch.com

Original post:
Adipose Tissue-Derived Stem Cells (ADSCS) Market Expected to Witness High Growth over the Forecast 2027 - BCFocus

Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results – PRNewswire

By Stell Cell Research

HOUSTON, Nov. 9, 2020 /PRNewswire/ -- Marker Therapeutics, Inc.(Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2020.

"This quarter, our Company reached a significant milestone by initiating our first Marker-sponsored studya Phase 2 trial of zelenoleucel or MT-401, our lead MultiTAA-specific T cell product candidate for the treatment of post-transplant acute myeloid leukemia," said Peter L. Hoang, President & CEO of Marker Therapeutics. "We have enrolled the first patient in the safety lead-in portion of the trial, and are in the process of scheduling the donor in order to manufacture the product."

Continued Mr. Hoang: "During this unprecedented time, we have made significant progress by enrolling additional clinical sites for our AML trial, advancing our manufacturing process, reducing production time by 50% and improving the potency of our MT-401 product, and entering the final phase of the construction of our new in-house cGMP manufacturing facility. I am extremely proud of the dedication and resolve that our team has shown during these challenging months. I want to acknowledge their hard work across the organization that went into achieving these milestones."

PROGRAM UPDATES

MT-401: Multi-Antigen Targeted (MultiTAA)-Specific T Cell Product Candidate for AML

Phase 2 AML Trial The Company initiated the safety lead-in portion of its Phase 2 study of zelenoleucel (MT-401) in patients with acute myeloid leukemia (AML) following an allogeneic stem cell transplant in both the adjuvant and active disease settings. The Company anticipates treating the first patient by Q1 2021. The safety lead-in is expected to enroll a total of six patients: three of which will be treated with MT-401 manufactured with a legacy reagent, and the remaining three to be treated with study drug manufactured with a new reagent from an alternate supplier.

Marker has activated four clinical sites and is in the start-up phase with additional clinical sites to enroll patients for the safety lead-in portion of the AML trial. The Company has also received commitments from additional clinical sites to participate in the Phase 2 AML trial following the safety lead-in phase and anticipates activating a total of approximately 20 sites.

The study remains on partial clinical hold pending the review of final data and subsequent acceptance of certificates of analysis for the new reagent by the U.S. FDA. The Company received the remaining reagent from the alternate supplier in Q3 2020 and is currently conducting the comparability analyses between the previous and new reagents, as required by FDA. Marker intends to submit all required data to FDA by Q1 2021 to enable removal of the partial clinical hold.

Over the past year, the Company has continued to streamline and simplify the MT-401 manufacturing process. The technical improvements include a 50% reduction in manufacturing time, a 95% reduction in the number of required operator interventions, and significant improvement in the consistency and reproducibility of the manufacturing process, while yielding a significant increase in the number of T cells available for patient administration. The Company expects the new process to yield a measurably improved product, with superior T cell phenotype and antigen specificity as compared to the original process. The new process improvements have been updated in the CMC section of the IND and will be used for all patients in the Marker AML clinical trial.

BUSINESS UPDATES

THIRD QUARTER 2020 FINANCIAL RESULTS

Cash Position and Guidance:At September 30, 2020, Marker had cash and cash equivalents of $27.0 million. The Company raised $2.2 million through the previously executed $30 million common stock purchase agreement with Aspire Capital Fund, LLC. The remaining $27.8 million available to Marker from Aspire Capital along with current cash available, funds operations into Q1 2022.

R&D Expenses:Research and development expenses were$4.8 million for the quarter endedSeptember 30, 2020, compared to$3.1 million for the quarter ended September 30, 2019.

G&A Expenses:General and administrative expenses were$2.6 million for the quarter endedSeptember 30, 2020, compared to $2.5 million for the quarter ended September 30, 2019.

Net Loss:Marker reported a net loss of$7.4 millionfor the quarter endedSeptember 30, 2020, compared to a net loss of$5.5 million for the quarter ended September 30, 2019.

Conference Call and Webcast

The Company will host a webcast and conference call to discuss its third quarter 2020 financial results and provide a corporate update today at 5:00 PM EST.

The webcast will be accessible in theInvestorssection of the Company's website at markertherapeutics.com. Individuals can participate in the conference call by dialing 877-407-8913 (domestic) or 201-689-8201 (international) and referring to the "Marker Therapeutics Third Quarter 2020 Earnings Call."

The archived webcast will be available for replay on the Marker website following the event.

About Marker Therapeutics, Inc. Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit:https://www.markertherapeutics.com/email-alerts

Forward-Looking Statement Disclaimer This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the impact of the COVID-19 pandemic; the timing, conduct and success of our clinical trials, as well as clinical trials conducted by our collaborators; our manufacturing processes and our ability to use our in-house manufacturing facility to support clinical and commercial demand. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Marker Therapeutics, Inc.

Condensed Consolidated Balance Sheets

September 30,

December 31,

2020

2019

(Unaudited)

(Audited)

ASSETS

Current assets:

Cash and cash equivalents

$ 26,956,737

$ 43,903,949

Prepaid expenses and deposits

2,367,145

1,526,442

Interest receivable

135

56,189

Other receivable

1,000,000

-

Total current assets

30,324,017

45,486,580

Non-current assets:

Property, plant and equipment, net

2,629,628

417,528

Construction in progress

4,557,581

-

Right-of-use assets, net

11,059,962

455,174

Total non-current assets

18,247,171

872,702

Total assets

$ 48,571,188

$ 46,359,282

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable and accrued liabilities

$ 5,746,149

$ 1,757,680

Lease liability

278,333

204,132

Warrant liability

-

31,000

Total current liabilities

6,024,482

1,992,812

Non-current liabilities:

Lease liability, net of current portion

11,948,781

280,247

Total non-current liabilities

11,948,781

280,247

Total liabilities

17,973,263

2,273,059

Commitments and contingencies

-

-

Stockholders' equity:

Preferred stock - $0.001 par value, 5 million shares authorized and 0 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively

-

-

Common stock, $0.001 par value, 150 million shares authorized, 48.0 million and 45.7 million shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively

48,025

45,728

Additional paid-in capital

378,282,157

371,573,909

Go here to see the original:
Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results - PRNewswire

CODA Biotherapeutics Receives Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health…

By Stell Cell Research

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform to treat neurological disorders and diseases with an initial focus on neuropathic pain and epilepsy, today announced it has been awarded a Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). As part of theNIH Helping to End Addiction Long-term InitiativeSM, or NIH HEAL InitiativeSM, the funding of $670,000 over two years will be used to support CODA's plans to evaluate and advance the Company's unique receptor-ligand pairs toward the clinic for the treatment of neuropathic pain. Orion P. Keifer, Jr. M.D., Ph.D., Vice President, Discovery and Translation at CODA, will serve as the program's principal investigator.

"We are unwavering in our commitment to developing novel chemogenetic therapies for the treatment of neurological disorders and diseases like neuropathic pain for which current treatment options have significant limitations," said Michael Narachi, President and Chief Executive Officer, CODA. "We are honored to receive this grant from NINDS, as this funding will help advance our chemogenetic platform toward human clinical trials where we hope to demonstrate transformative results for patients."

CODA Biotherapeutics is developing a paradigm-shifting gene therapy approach for neuropathic pain by deploying a chemogenetic strategy for treating neuropathic pain sensations at their origin. The Company's innovative treatment aims to modulate specific neuronal circuits where pain arises via adeno-associated virus-mediated delivery of an engineered inhibitory receptor. The receptor is designed to be quiescent in the transduced cells but will specifically and dose-dependently inhibit neurons when exposed to a novel, orally bioavailable small-molecule agonist. CODA expects this treatment will produce substantially improved and durable pain relief while potentially avoiding off-target/adverse effects of currently available treatments.

The NINDS SBIR/Small Business Technology Transfer (STTR) program funds small business concerns to conduct innovative neuroscience research and/or development that has both the potential for commercialization and public health benefit.

In addition, CODA was recently selected to collaborate with NIH's National Center for Advancing Translational Science (NCATS), also as part of the NIH HEAL initiative. CODA will partner with the Stem Cell Translation Laboratory led by Ilyas Singec, M.D., Ph.D., in the NCATS Division of Preclinical Innovation (DPI) in developing induced pluripotent stem cell (iPSC)-derived human Ab sensory neurons for the identification and characterization of novel neuropathic pain therapies. The joint NCATS/CODA collaboration will leverage expertise and technologies available at Dr. Singec's lab to jointly develop protocols for generating iPSC-derived A primary sensory neurons, which CODA will then use for the identification and evaluation of inhibitory chemogenetic receptors for the treatment of neuropathic pain. G. Steven Dodson, Ph.D., Vice President of Pharmacology and Early Development at CODA will serve as lead collaborator.

"Ab neurons are a key cell type for the evaluation of our receptor-ligand combinations and their development should advance the translational understanding of how our approach may impact pain states in patients. Through this partnership, CODA will collaborate with and gain access to the scientific capabilities, expertise, state-of-the-art technologies, and resources of the NCATS DPI to develop iPSC-derived human Ab sensory neurons, which will help us progress our neuropathic pain therapies toward the clinic," added Mr. Narachi.

About Neuropathic Pain According to a study published in the Journal of Pain Research, 10 percent of the U.S. population suffers from neuropathic pain an estimated 30 million Americans. Neuropathic pain is caused by damage or disease of the sensory system, leading to chronic debilitation and loss of quality of life. Current pharmacological therapies for chronic neuropathic pain, such as opioids, anticonvulsants, and tricyclic anti-depressants, are not always effective and can have side effects, including the potential for addiction.

About the CODA Platform CODA's chemogenetic platform aims to reverse the aberrant neuronal activity underlying many neurological disorders. With chemogenetics, dysfunctional neurons are modified using optimized adeno-associated virus (AAV) vectors delivered directly to them by standard-of-care neurosurgical procedures. The AAV vectors encode ligand-gated ion channels (chemogenetic receptors) that are highly responsive to specific proprietary small molecule therapeutics but are otherwise inactive. The activity of these receptors, and thus the aberrant activity of the modified neurons, is controlled in a selective and tunable manner through administration of the small molecule to generate therapeutic benefit with minimal side effects.

About CODA Biotherapeutics CODA Biotherapeutics, Inc., is a preclinical-stage biopharmaceutical company developing an innovative gene therapy platform to treat neurological disorders and diseases. The Company is creating the ability to control neurons with its revolutionary chemogenetics-based technology. CODA is located in South San Francisco, CA. For more information, please visit http://www.codabiotherapeutics.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/coda-biotherapeutics-receives-grant-from-the-national-institute-of-neurological-disorders-and-stroke-ninds-of-the-national-institutes-of-health-nih-to-help-advance-its-next-generation-gene-therapy-mediated-chemogenetic-platfor-301168028.html

SOURCE CODA Biotherapeutics, Inc.

View original post here:
CODA Biotherapeutics Receives Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health...

Coadministration of endothelial and smooth muscle cells derived from human induced pluripotent stem cells as a therapy for critical limb ischemia -…

By Induced Pluripotent Stem Cells

This article was originally published here

Stem Cells Transl Med. 2020 Nov 11. doi: 10.1002/sctm.20-0132. Online ahead of print.

ABSTRACT

Critical limb ischemia is a condition in which tissue necrosis occurs due to arterial occlusion, resulting in limb amputation in severe cases. Both endothelial cells (ECs) and vascular smooth muscle cells (SMCs) are needed for the regeneration of peripheral arteries in ischemic tissues. However, it is difficult to isolate and cultivate primary EC and SMC from patients for therapeutic angiogenesis. Induced pluripotent stem cells (iPSCs) are regarded as useful stem cells due to their pluripotent differentiation potential. In this study, we explored the therapeutic efficacy of human iPSC-derived EC and iPSC-derived SMC in peripheral artery disease model. After the induction of mesodermal differentiation of iPSC, CD34+ progenitor cells were isolated by magnetic-activated cell sorting. Cultivation of the CD34+ progenitor cells in endothelial culture medium induced the expression of endothelial markers and phenotypes. Moreover, the CD34+ cells could be differentiated into SMC by cultivation in SMC culture medium. In a murine hindlimb ischemia model, cotransplantation of EC with SMC improved blood perfusion and increased the limb salvage rate in ischemic limbs compared to transplantation of either EC or SMC alone. Moreover, cotransplantation of EC and SMC stimulated angiogenesis and led to the formation of capillaries and arteries/arterioles in vivo. Conditioned medium derived from SMC stimulated the migration, proliferation, and tubulation of EC in vitro, and these effects were recapitulated by exosomes isolated from the SMC-conditioned medium. Together, these results suggest that iPSC-derived SMC enhance the therapeutic efficacy of iPSC-derived EC in peripheral artery disease via an exosome-mediated paracrine mechanism.

PMID:33174379 | DOI:10.1002/sctm.20-0132

The rest is here:
Coadministration of endothelial and smooth muscle cells derived from human induced pluripotent stem cells as a therapy for critical limb ischemia -...

Induced Pluripotent Stem Cells (iPSCs) Market Size, Drivers, Potential Growth Opportunities, Competitive Landscape, Trends And Forecast To 2027 -…

By Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells (iPSCs) Market Overview

The Global Induced Pluripotent Stem Cells (iPSCs) Market is showing positive signs of growth. With the current COVID-19 pandemic scenario, new business opportunities are sprouting in the market. Organizations must explore new markets to expand their business globally and locally. For getting a deeper understanding of the emerging trends, the Global Induced Pluripotent Stem Cells (iPSCs) Market report showcases various factors that drive the economy worldwide. Moreover, the companies will get to know the market landscape for the next decade 2020-2027.

The Global Induced Pluripotent Stem Cells (iPSCs) Market report has been uniquely designed to cater to the needs of the businesses of the 21st century. Going digital is the new normal. Moreover, companies can get to understand their strengths and weaknesses after assessing the market. The next decade is going to be ruled by customer-centric services. To align the business operations, the management team can utilize the actionable recommendations offered at the end of the Global Induced Pluripotent Stem Cells (iPSCs) Market report. Factors that can lift or reduce the business are termed as the external factors that also govern the functioning of the market or industries as a whole.

Before designing the blueprint, every business group can go through the Global Induced Pluripotent Stem Cells (iPSCs) Market report to understand the key business areas. For shaping a new business venture or expanding into a new market, every company must look into the opportunities and threats that are lurking in the current market. To make an efficient business plan, corporations need to understand the market dynamics that will shape the market in the forecast period (2020-2027).

Following key players have been profiled with the help of proven research methodologies:

Induced Pluripotent Stem Cells (iPSCs) Market: Competitive Landscape

To get a head start in a new market, every enterprise needs to understand the competitive landscape and the basic rules that have kept the specific market afloat. The global Induced Pluripotent Stem Cells (iPSCs) Market report unravels the secret ingredients used by competitors to meet the demands of their target audience. For specifically understanding the need to balance the capital invested with profits, organizations must use specific indicators. These indicators will not only help in pointing towards growth but also act as an alert to the upcoming threats in the near future. A proper business plan and approach can guarantee a smooth path ahead for every organization.

If the firms believe in offering a memorable experience to their prospective customers, the Global Induced Pluripotent Stem Cells (iPSCs) Market report is going to be very useful. Facts and figures are churned into this investigative report to share the strengths and weaknesses of the company. With new technologies being introduced every day, many new entrants have started their business in the market. So, to understand their approach towards the market, the Global Induced Pluripotent Stem Cells (iPSCs) Market report has a dedicated section. From the financial aspect to legal, the market report covers all the major things required to study the market and put the business plan in action. Not only this, the competitors added in the report can be altered as per the clients needs and expectations. Furthermore, the companies get a basic outline of moves, in the Global Induced Pluripotent Stem Cells (iPSCs) Market report, that can push the business to emerald heights, both in terms of sales and customer generation for the estimated time frame (2020-2027).

Induced Pluripotent Stem Cells (iPSCs) Market Segmentation:

The Induced Pluripotent Stem Cells (iPSCs) Market has been examined into different global market segments such as type, applications, and global geographies. Each and every global market segment has been studied to get informative insights into various global regions.

Induced Pluripotent Stem Cells (iPSCs) Market Segment by Type:

Induced Pluripotent Stem Cells (iPSCs) Market Segment by Application:

Induced Pluripotent Stem Cells (iPSCs) Market Segment by Global Presence:

North America Latin America Middle East Asia-Pacific Africa Europe

The report has been aggregated by using a couple of research methodologies such as primary and secondary research techniques. It helps in collecting informative pieces of professional information for deriving effective insights into the market. This informative report helps in making well informed and strategic decisions throughout the forecast period.

Induced Pluripotent Stem Cells (iPSCs) Market: Scope of the Report

To properly get a deeper understanding of the Global Induced Pluripotent Stem Cells (iPSCs) Market, this detailed report is the best choice for businesses. To boost the business along with gaining an edge over the competition, every enterprise needs to focus on the pain points of the market (under investigation). Our experienced professionals have collated facts and figures.

This in-depth analysis has revealed many fascinating facts for organizations. For smooth functioning, every business needs to be flexible towards the latest market trends. For this, the framework must be designed to adapt to the trends running at the moment. An end-to-end examination done on the target crowd helped in building the fundamental segment of the investigation, namely the external factors. These have a high tendency to push or pull the industries. Entire industries can either flourish or wipe out due to these uncontrollable factors. Global Induced Pluripotent Stem Cells (iPSCs) market report shows the most affordable options for new as well as established business players to gain market share.

With the highly experienced and motivated team at your service, the team also provides the impact of major factors such as Porters five forces. In the Global Induced Pluripotent Stem Cells (iPSCs) Market, every business runs on the image that is generated digitally in the current decade. Hence, companies need to understand the legal hurdles also. Moreover, with the in-depth study conducted across the various market verticals, it is crystal clear that stakeholders also play a significant role in running the business. Get all the details in the Global Induced Pluripotent Stem Cells (iPSCs) Market report and understand your competitors.

Key questions answered through this analytical market research report include:

What are the latest trends, new patterns and technological advancements in the Induced Pluripotent Stem Cells (iPSCs) Market? Which factors are influencing the Induced Pluripotent Stem Cells (iPSCs) Market over the forecast period? What are the global challenges, threats and risks in the Induced Pluripotent Stem Cells (iPSCs) Market? Which factors are propelling and restraining the Induced Pluripotent Stem Cells (iPSCs) Market? What are the demanding global regions of the Induced Pluripotent Stem Cells (iPSCs) Market? What will be the global market size over the coming future? What are the different effective business strategies followed by global companies?

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

More:
Induced Pluripotent Stem Cells (iPSCs) Market Size, Drivers, Potential Growth Opportunities, Competitive Landscape, Trends And Forecast To 2027 -...

Proteintech and HebeCell Announce Collaboration on Nanobody iPSC-derived Natural Killer Cells – BioSpace

By Induced Pluripotent Stem Cells

Proteintechs recent acquisition of nanobody manufacturer, ChromoTek, has made them a leading player in the nanobody space. ChromoTeks high-performing camelid single-chain recombinant reagents, also known as nanobodies, fuel breakthrough research discoveries.

HebeCell holds unique expertise and intellectual property in induced pluripotent stem cells (iPSC) and their lineage specific differentiation, especially toward natural killer (NK) cells. Although NK cells are best known for killing virally infected cells, they also play key roles in detecting and controlling early signs of cancer.

Partnering with Proteintech will give both companies a competitive edge, said Dr. Allen Feng, the Founder and Chief Scientific Officer of HebeCell, Our combined expertise and technologies create a unique and special collaboration that will improve the treatment and care of cancer patients.

Dr. Jason Li, CEO of Proteintech added, Ive known Dr. John Lu, Founder and CEO of HebeCell, for many years and Im glad we have an opportunity to work together on this important project. With HebeCells proprietary NK cells and Proteintechs nanobodies, the two companies can transform the future of cancer therapy.

About Proteintech Group Inc.

Proteintech is a leading manufacturer of antibodies, proteins and immunoassays across research areas. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering 2/3 of the human proteome. Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade. After the acquisition of manufacturer, ChromoTek, Proteintech now provides innovative reagents based on camelid antibodies called nanobodies. Proteintech sites are ISO13485 and ISO9001-2015 accredited.

About HebeCell Corporation

HebeCell, founded in 2016, focuses on the fields of Immunotherapy by developing human induced pluripotent stem cell (iPSC)-based off-the-shelf CAR-natural killer (CAR-NK) and other immune cell therapeutics targeting hematological malignancies and solid tumors, as well as autoimmune and infectious diseases. HebeCell has expertise and assets in iPSC specific lineage cell differentiation and state-of-the-art cGMP cell manufacturing facility. Its first-in-class proprietary 3D manufacturing platform for human iPSC-CAR-NK cells is feeder-free and designed specifically for single-use-bioreactor at industrial scale, which allows rapid deploy off-the-shelf CAR-NK cell products for all patients. HebeCells platform technology will accelerate the application of iPSC cells as a viable source of immune cells in the next generation of immunotherapy and will alter the CAR-NK cell therapy field by delivering cost effective allogenic therapeutics worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201111005786/en/

See the rest here:
Proteintech and HebeCell Announce Collaboration on Nanobody iPSC-derived Natural Killer Cells - BioSpace

Global Induced Pluripotent Stem Cells Market Analysis Trends, Growth Opportunities, Size, Type, Dynamic Demand and Drives with Forecast to 2026 -…

By Induced Pluripotent Stem Cells

There are millions of them around the globe waiting for clutching on to some of the latest vital information circulating across the globe. The up-to-the-minute Induced Pluripotent Stem Cells market report based on the growth and the development of theInduced Pluripotent Stem Cells marketis systematically listed down. The Induced Pluripotent Stem Cells market report comprises statistically verified facts such the unique essence including topological investigations, worldwide market share, government stringent norms, applications, current trends, futuristic plans, market bifurcations, and so on mentioned in a crystal clear pattern.

The statistical plus scientific Induced Pluripotent Stem Cells market report has all the important market aspects penciled down in a layman language format so that the data based on the markets productivity or future strategy can be easily extrapolated from the reports. The Induced Pluripotent Stem Cells market report has the dominant market players Fate Therapeutics, Waisman Biomanufacturing, Bone Therapeutics SA, System Biosciences, Ocata Therapeutics Inc., BrainStorm Cell Therapeutics Inc., CellTherapies P/L, Cellular Dynamics, Lonza, Cellectics, Regeneus Ltd., Stemgent, Iperian, Organogenesis Inc explained in detail.

Sample of global Induced Pluripotent Stem Cells Market Report at::https://www.marketresearchstore.com/report/global-induced-pluripotent-stem-cells-market-report-2020-764003#RequestSample

The essential futuristic segments such as {Adult Sources, Fetal Sources, Others}; {Hematopoietic stem cell transplantation, Tissue repair damage, Autoimmune diseases, As gene therapy vectors.} have also been detailed out in the Induced Pluripotent Stem Cells market report for the clients convenience and more of vital data embracing capability. The forecast trends along with the current market status can better understand the Induced Pluripotent Stem Cells market development on a global basis. The intricate industrial strategies and the supply-demand chain are also discussed in the contextual report.

Key points of the global Induced Pluripotent Stem Cells market

Theoretical analysis of the global Induced Pluripotent Stem Cells market stimulators, products, and other vital facets Recent, historical, and future trends in terms of revenue and market dynamics are reported Pin-point analysis of the competitive market dynamics and investment structure is predicted to grow Future market trends, latest innovations, and various business strategies are reported Market dynamics include growth influencers, opportunities, threats, challenges, and other crucial facets

The Induced Pluripotent Stem Cells market report has the imperative data mentioned in a systematic way only after comprehensive inspection and vigilant referencing. The diagrammatic representations such as a pie chart of the Induced Pluripotent Stem Cells market are also drawn out so as to attract the punters and make it easy for them to comprehend the entire Induced Pluripotent Stem Cells market from in and out. The most eye-catching format of the Induced Pluripotent Stem Cells market report is its market bifurcation based on the product type, application, geography, end-users, and more as per the particular market. The geographical segments Europe, North America, Latin America, Asia Pacific, and Middle East & Africa are further exhaustively mentioned.

Read Detailed Index of full Research Study at::https://www.marketresearchstore.com/report/global-induced-pluripotent-stem-cells-market-report-2020-764003

Questions answered in the report include

1. What is the expected market size by the end of the forecast period? 2. What are the major factors initiating the global Induced Pluripotent Stem Cells market growth? 3. What are the latest developments and trending market strategies that are influencing the growth of the Induced Pluripotent Stem Cells market? 4. What are the key outcomes of the Induced Pluripotent Stem Cells market developments? 5. Who are the key players in the market? 6. What are the opportunities and challenges faced by the key players?

The Induced Pluripotent Stem Cells market report endows the global market dominance, market segmentation, growth factors, and others reported such that the clients can have a total tour of the market without any much off efforts needed.

Key Reasons for Purchasing Global Induced Pluripotent Stem Cells Market Report

New approaches and latest development trend that describe the structure of the market Advanced market breakdown structure Historical data and future market scope In-depth market analysis based on statistics, growth stimulators, and market developments Statistical data representation through figurative, numerical, and theoretical elaboration Report provides insight of the business and sales activities

Ask Any Kind of Query Before Purchasing the Report Here:https://www.marketresearchstore.com/report/global-induced-pluripotent-stem-cells-market-report-2020-764003#InquiryForBuying

Read more from the original source:
Global Induced Pluripotent Stem Cells Market Analysis Trends, Growth Opportunities, Size, Type, Dynamic Demand and Drives with Forecast to 2026 -...

Stem Cell Manufacturing Market Share & Size, Future Growth, Trends Evaluation, Demands, Regional Analysis and Forecast to 2027| Merck Group,…

By Induced Pluripotent Stem Cells

A New business Strategy report released by DBMR with title Global Stem Cell Manufacturing Market (COVID-19 Version) Study Forecast till 2027. This Market report brings data for the estimated year 2020 and forecasted till 2027 in terms of both, value (US$ MN) and volume (MT).The report also consists of forecast factors, macroeconomic factors, and a market outlook of the market. The study is conducted by applying both top-down and bottom-up approaches and further iterative methods used to validate and size market estimation and trends of the Global Stem Cell Manufacturing Market. This report provides information regarding Stem Cell Manufacturing market size, trends, growth, cost structure, capacity, revenue and forecast 2027.The report explains the moves of top market players and brands that range from developments, product launches, acquisitions, mergers, joint ventures, trending innovation and business policies. Additionally to compliment insights EXIM data, consumption, supply and demand Figures, raw price analysis, market revenue and gross margins.

Stem cell manufacturing is forecasted to grow at CAGR of 6.42% to an anticipated value of USD 18.59 billion by 2027 with factors like rising awareness towards diseases like cancer, degenerative disorders and hematopoietic disorders is driving the growth of the market in the forecast period of 2020-2027.

Download Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this[emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-manufacturing-market&AB

Stem cell manufacturing has shown an exceptional penetration in North America due to increasing research in stem cell. Increasing research and development activities in biotechnology and pharmaceutical sector is creating opportunity for the stem cell manufacturing market.

The Global Stem Cell Manufacturing Market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Stem Cell Manufacturing Market Share analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed.

Global Stem Cell Manufacturing Market Segematation By Product (Stem Cell Line, Instruments, Culture Media, Consumables), Application (Research Applications, Clinical Applications, Cell and Tissue Banking), End Users (Hospitals and Surgical Centers, Pharmaceutical and Biotechnology Companies, Clinics, Community Healthcare, Others)

List of TOP KEY PLAYERS in Stem Cell Manufacturing Market Report are

Thermo Fisher Scientific Merck KGaA BD JCR Pharmaceuticals Co., Ltd Organogenesis Inc Osiris Vericel Corporation AbbVie Inc AM-Pharma B.V ANTEROGEN.CO.,LTD Astellas Pharma Inc Bristol-Myers Squibb Company FUJIFILM Cellular Dynamics, Inc RHEACELL GmbH & Co. KG Takeda Pharmaceutical Company Limited Teva Pharmaceutical Industries Ltd ViaCyte,Inc VistaGen Therapeutics Inc GlaxoSmithKline plc ..

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)@https://www.databridgemarketresearch.com/toc/?dbmr=global-stem-cell-manufacturing-market&AB

The report can help to understand the market and strategize for business expansion accordingly. In the strategy analysis, it gives insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the Stem Cell Manufacturing industry. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. For each manufacturer covered, this report analyzes their Stem Cell Manufacturing manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The Global Stem Cell Manufacturing Market Trends, development and marketing channels are analysed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

Global Stem Cell Manufacturing Market Scope and Market Size

Stem cell manufacturing market is segmented on the basis of product, application and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on product, the stem cell manufacturing market is segmented into stem cell lines, instruments, culture media and consumables. Stem cell lines are further segmented into induced pluripotent stem cells, embryonic stem cells, multipotent adult progenitor stem cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells. Instrument is further segmented into bioreactors and incubators, cell sorters and other instruments.

On the basis of application, the stem cell manufacturing market is segmented into research applications, clinical applications and cell and tissue banking. Research applications are further segmented into drug discovery and development and life science research. Clinical applications are further segmented into allogenic stem cell and autologous stem cell therapy.

On the basis of end users, the stem cell manufacturing market is segmented into hospitals and surgical centers, pharmaceutical and biotechnology companies, research institutes and academic institutes, community healthcare, cell banks and tissue banks and others.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Stem cell manufacturing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for stem cell manufacturing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the stem cell manufacturing market. The data is available for historic period 2010 to 2018.

The Global Stem Cell Manufacturing Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of stem cell manufacturing market for global, Europe, North America, Asia Pacific and South America.

Key Insights in the report:

Historical and current market size and projection up to 2025

Market trends impacting the growth of the global taste modulators market

Analyze and forecast the taste modulators market on the basis of, application and type.

Trends of key regional and country-level markets for processes, derivative, and application Company profiling of key players which includes business operations, product and services, geographic presence, recent developments and key financial analysis

For More Information or Query or Customization Before Buying, Visit @https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-manufacturing-market&AB

Opportunities in the market

To describe and forecast the market, in terms of value, for various segments, by region North America, Europe, Asia Pacific (APAC), and Rest of the World (RoW)

The key findings and recommendations highlight crucial progressive industry trends in the Stem Cell manufacturing Market, thereby allowing players to develop effective long term strategies

To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, and detail the competitive landscape for market leaders Extensive analysis of the key segments of the industry helps in understanding the trends in types of point of care test across Europe.

To get a comprehensive overview of the Stem Cell manufacturing market.

With tables and figures helping analyses worldwide Global Stem Cell Manufacturing Market Forecast this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. There are 15 Chapters to display the Stem Cell Manufacturing market.

Chapter 1, About Executive Summary to describe Definition, Specifications and Classification of Stem Cell Manufacturing market, By Product Type, by application, by end users and regions.

Chapter 2, objective of the study.

Chapter 3, to display Research methodology and techniques.

Chapter 4 and 5, to show the Stem Cell Manufacturing Market Analysis, segmentation analysis, characteristics;

Chapter 6 and 7, to show Five forces (bargaining Power of buyers/suppliers), Threats to new entrants and market condition;

Chapter 8 and 9, to show analysis by regional segmentation[North America, Europe, Asia-Pacific etc ], comparison, leading countries and opportunities; Regional Marketing Type Analysis, Supply Chain Analysis

Chapter 10, to identify major decision framework accumulated through Industry experts and strategic decision makers;

Chapter 11 and 12, Stem Cell Manufacturing Market Trend Analysis, Drivers, Challenges by consumer behavior, Marketing Channels

Chapter 13 and 14, about vendor landscape (classification and Market Ranking)

Chapter 15, deals with Stem Cell Manufacturing Market sales channel, distributors, Research Findings and Conclusion, appendix and data source.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia or Oceania [Australia and New Zealand]

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Originally posted here:
Stem Cell Manufacturing Market Share & Size, Future Growth, Trends Evaluation, Demands, Regional Analysis and Forecast to 2027| Merck Group,...

Induced Pluripotent Stem Cells Market Comprehensive Insights, Growth, Forecast and Covid-19 Impact by 2026 | Medipost Co. Ltd., Ocata Therapeutics…

By Induced Pluripotent Stem Cells

Global Induced Pluripotent Stem Cells market report offers a precise outline of the market that includes many aspects of market product definition, market segmentation, analysis, key developments, and existing vendors state of the business. These Induced Pluripotent Stem Cells industry documents include key players and geographical markets that have adopted vital methodologies for business developments and growth. The consumer trust in precise and proper Induced Pluripotent Stem Cells information structures that is employed for analysis of the business Report 2020 has the aim to deliver a complete analysis of the Induced Pluripotent Stem Cells market. The report could assist you in coming up with worthy growth methods and additionally aware and indurate challenges.

Perpetually increasing in the market, often rise in customers demands are the notable factors of growing and developing the business. Taking thought of each segments Induced Pluripotent Stem Cells market report is deliberate by creating each analysis of the market conditions worldwide. Examine the restraining Induced Pluripotent Stem Cells segments affecting the business in the coming future has been into consideration.

Get a Sample Copy of the Report at https://www.futuristicreports.com/request-sample/52069

Impact of COVID-19 on Induced Pluripotent Stem Cells Market

The report also contains the effect of the ongoing worldwide pandemic, i.e., COVID-19, on the Induced Pluripotent Stem Cells Market and what the future holds for it. It offers an analysis of the impacts of the epidemic on the international market. The epidemic has immediately interrupted the requirement and supply series. The report also assesses the economic effect on firms and monetary markets. Futuristic Reports has accumulated advice from several delegates of this business and has engaged from the secondary and primary research to extend the customers with strategies and data to combat industry struggles throughout and after the COVID-19 pandemic.

Global Induced Pluripotent Stem Cells Market: Competitive Landscape

(Medipost Co. Ltd., Ocata Therapeutics Inc., Lonza, Regeneus Ltd., Fate Therapeutics, Organogenesis Inc., Waisman Biomanufacturing, Cellectics, Stemgent, CellTherapies P/L, Cellular Dynamics, BrainStorm Cell Therapeutics Inc., Viacyte, Axiogenesis, System Biosciences, Bone Therapeutics SA, Reprocell, Iperian)

Segment by Type, the Induced Pluripotent Stem Cells market is segmented into

Adult Sources Fetal Sources Others

Segment by Application, the Induced Pluripotent Stem Cells market is segmented into

Hematopoietic stem cell transplantation Tissue repair damage Autoimmune diseases As gene therapy vectors.

To Understand How Covid-19 Impact Is Covered in This Report With additional Discount: https://www.futuristicreports.com/check-discount/52069

This report also splits the market by region:

United States Canada Mexico Brazil APAC China Japan Korea

Key Questions Answered in The Report:

Market Report includes major TOC points 1 Study Coverage 1.1 Induced Pluripotent Stem Cells Product Introduction 1.2 Market Segments 1.3 Key Induced Pluripotent Stem Cells Manufacturers Covered: Ranking by Revenue 1.4 Market by Type 1.4.1 Global Induced Pluripotent Stem Cells Market Size Growth Rate by Type 1.4.2 Measuring Smart Plug 1.4.3 Regular Smart Plug 1.4.4 Remote Control Smart Plug 1.4.5 Other 1.5 Market by Application 1.5.1 Global Induced Pluripotent Stem Cells Market Size Growth Rate by Application 1.5.2 Home 1.5.3 Commercial 1.6 Study Objectives 1.7 Years Considered

2 Executive Summary 2.1 Global Induced Pluripotent Stem Cells Market Size, Estimates and Forecasts 2.1.1 Global Induced Pluripotent Stem Cells Revenue 2016-2026 2.1.2 Global Induced Pluripotent Stem Cells Sales 2016-2026 2.2 Global Induced Pluripotent Stem Cells, Market Size by Producing Regions: 2016 VS 2020 VS 2026 2.3 Induced Pluripotent Stem Cells Historical Market Size by Region (2016-2020) 2.3.1 Global Induced Pluripotent Stem Cells Retrospective Market Scenario in Sales by Region: 2016-2020 2.3.2 Global Induced Pluripotent Stem Cells Retrospective Market Scenario in Revenue by Region: 2016-2020 2.4 Induced Pluripotent Stem Cells Market Estimates and Projections by Region (2021-2026) 2.4.1 Global Induced Pluripotent Stem Cells Sales Forecast by Region (2021-2026) 2.4.2 Global Induced Pluripotent Stem Cells Revenue Forecast by Region (2021-2026)

3 Global Induced Pluripotent Stem Cells Competitor Landscape by Players 3.1 Global Top Induced Pluripotent Stem Cells Sales by Manufacturers 3.1.1 Global Induced Pluripotent Stem Cells Sales by Manufacturers (2016-2020) 3.1.2 Global Induced Pluripotent Stem Cells Sales Market Share by Manufacturers (2016-2020) 3.2 Global Induced Pluripotent Stem Cells Manufacturers by Revenue 3.2.1 Global Induced Pluripotent Stem Cells Revenue by Manufacturers (2016-2020) 3.2.2 Global Induced Pluripotent Stem Cells Revenue Share by Manufacturers (2016-2020) 3.2.3 Global Induced Pluripotent Stem Cells Market Concentration Ratio (CR5 and HHI) (2016-2020) 3.2.4 Global Top 10 and Top 5 Companies by Induced Pluripotent Stem Cells Revenue in 2019 3.2.5 Global Induced Pluripotent Stem Cells Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Global Induced Pluripotent Stem Cells Price by Manufacturers 3.4 Global Induced Pluripotent Stem Cells Manufacturing Base Distribution, Product Types 3.4.1 Induced Pluripotent Stem Cells Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Induced Pluripotent Stem Cells Product Type 3.4.3 Date of International Manufacturers Enter into Induced Pluripotent Stem Cells Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2016-2026) 4.1 Global Induced Pluripotent Stem Cells Market Size by Type (2016-2020) 4.1.1 Global Induced Pluripotent Stem Cells Sales by Type (2016-2020) 4.1.2 Global Induced Pluripotent Stem Cells Revenue by Type (2016-2020) 4.1.3 Induced Pluripotent Stem Cells Average Selling Price (ASP) by Type (2016-2026) 4.2 Global Induced Pluripotent Stem Cells Market Size Forecast by Type (2021-2026) 4.2.1 Global Induced Pluripotent Stem Cells Sales Forecast by Type (2021-2026) 4.2.2 Global Induced Pluripotent Stem Cells Revenue Forecast by Type (2021-2026) 4.2.3 Induced Pluripotent Stem Cells Average Selling Price (ASP) Forecast by Type (2021-2026) 4.3 Global Induced Pluripotent Stem Cells Market Share by Price Tier (2016-2020): Low-End, Mid-Range, and High-End

5 Market Size by Application (2016-2026) 5.1 Global Induced Pluripotent Stem Cells Market Size by Application (2016-2020) 5.1.1 Global Induced Pluripotent Stem Cells Sales by Application (2016-2020) 5.1.2 Global Induced Pluripotent Stem Cells Revenue by Application (2016-2020) 5.1.3 Induced Pluripotent Stem Cells Price by Application (2016-2020) 5.2 Induced Pluripotent Stem Cells Market Size Forecast by Application (2021-2026) 5.2.1 Global Induced Pluripotent Stem Cells Sales Forecast by Application (2021-2026) 5.2.2 Global Induced Pluripotent Stem Cells Revenue Forecast by Application (2021-2026) 5.2.3 Global Induced Pluripotent Stem Cells Price Forecast by Application (2021-2026)

..Continued

Inquire or Share Your Questions If Any before the Purchasing This Report https://www.futuristicreports.com/send-an-enquiry/52069

Our Other Reports:

Pre-Shave Market Qualitative, Quantitative Research on Leading Players and Covid-19 Impact by 2026 | Beiersdorf AG, Godrej Group, Johnson & Johnson and Others

Silicon Plate Market by Type, Product Analysis, Applications and Covid-19 Impact by 2026 | Shin-Etsu Chemical, GlobalWafers, Ferrotec and Others

Car Holder Market Detailed Analysis, Regional Outlook and Covid-19 Impact by 2026 | Philips, X-power, VOSSON and Others

Bathtub Spouts Market In-Depth Study: Trends, Analysis and Covid-19 Impact by 2026 | MKH, California Faucets, Palazzani.EU and Others

Futuristic Reports

Name: Mark Rivera Tel: +1-408-520-9037 Email: [emailprotected]

See original here:
Induced Pluripotent Stem Cells Market Comprehensive Insights, Growth, Forecast and Covid-19 Impact by 2026 | Medipost Co. Ltd., Ocata Therapeutics...

Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205 (Universal E-CEL Cell Therapy) to…

By Stem Cell Medicine

Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205

About Regenerative Medicine Advanced Therapy (RMAT) DesignationEstablished under the 21st Century Cures Act, the RMAT designation was established to facilitate development and expedite review of cell therapies and regenerative medicines intended to treat serious or life-threatening diseases or conditions. Advantages include the benefits of the FDA's Fast Track and Breakthrough Therapy Designation programs, such as early interactions with the FDA to discuss potential surrogate or intermediate endpoints to support accelerated approval.

About HDT-AHCT High-dose therapy and autologous hematopoietic cell transplantation (HDT-AHCT) is considered a standard-of-care therapy for patients with aggressive systemic Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).Although efficacious and considered a potential cure, HDT-AHCT is associated with severe regimen-related toxicities (SRRT) that increase patient morbidity and risk for mortality, especially in the aging population. Effective prevention of SRRT may lead to more patients being eligible for a potential cure through HDT and stem cell transplantation.

About SRRT Consequences of Diffuse Injury to the Organ Vascular NichesThe human body is capable of renewing, healing and restoring organs.For example, the human oral-GI tract renews its lining every 3 to 7 days. Both the organ renewal and healing processes are dependent on organ stem cell vascular niches made up of stem cells, endothelial cells (cells that line blood vessels) and supportive cells.When tissues are injured, the vascular niche endothelial cells direct the stem cells, via angiocrine factor expression, to repair and restore the damaged tissue. This restorative capacity is most active during childhood and youth but starts to diminish with increasing age.HDT provided to eradicate cancer cells also cause diffuse, collateral damage to vascular niches of multiple healthy organs. In particular, the organs with the highest cell turnover (ones with most active vascular niches) are severely affected.Specifically, the oral-GI tract, dependent on constant renewal of its mucosal lining, starts to break down upon vascular niche injury.The mucosal breakdown can cause severe nausea, vomiting and diarrhea. In addition, the bacteria in the gut may escape into the circulation, resulting in patients becoming ill with endotoxemia, bacteremia or potentially lethal sepsis.HDT-related vascular niche damage can also occur in other organs resulting in severe or life-threatening complications involving the lung, heart, kidney, or the liver.Collectively, these complications are known as severe regimen-related toxicities or SRRT.SRRT can occur as frequently as 50% in lymphoma HDT-AHCT patients, with increased rate and severity in older patients.

About AB205AB-205 is a first-in-class engineered cell therapy consisting of proprietary 'universal' E-CEL (human engineered cord endothelial) cells.The AB-205 cells are intravenously administered after the completion of HDT on the same day as when the patient's own (autologous) blood stem cells are infused. AB-205 acts promptly to repair injured vascular niches of organs damaged by HDT.By repairing the vascular niches, AB-205 restores the natural process of tissue renewal, vital for organs such as oral-GI tract and the bone marrow. Successful and prompt organ restoration can prevent or reduce SRRT, an outcome that is beneficial to quality of life and cost reductive to the healthcare system.

About CIRMThe California Institute for Regenerative Medicine (CIRM) was established in November, 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure provided $3 billion in funding for California universities and research institutions.With over 300 active stem cell programs in their portfolio, CIRM is the world's largest institution dedicated to stem cell research. For more information, visit http://www.cirm.ca.gov.

About Angiocrine Bioscience Inc.Angiocrine Bioscience is a clinical-stage biotechnology company developing a new and unique approach to treating serious medical conditions associated with the loss of the natural healing and regenerative capacity of the body.Based on its novel and proprietary E-CEL platform, Angiocrine is developing multiple therapies to address unmet medical needs in hematologic, musculoskeletal, gastrointestinal, soft-tissue, and degenerative/aging-related diseases.A Phase 3 registration trial is being planned for the intravenous formulation of AB-205 for the prevention of severe complications in lymphoma patients undergoing curative HDT-AHCT.This AB-205 indication is covered by the Orphan Drug Designation recently granted by the US FDA.In addition, Angiocrine is conducting clinical trials of local AB-205 injections for the treatment of: (1) rotator cuff tear in conjunction with arthroscopic repair; and, (2) non-healing perianal fistulas in post-radiation cancer patients.

For additional information, please contact:

Angiocrine Bioscience, Inc. John R. Jaskowiak (877) 784-8496 [emailprotected]

SOURCE Angiocrine Bioscience, Inc.

Link:
Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205 (Universal E-CEL Cell Therapy) to...

→←